Robert Daniel Beauchamp

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6437314/publications.pdf

Version: 2024-02-01

96 papers	8,496 citations	36303 51 h-index	42399 92 g-index
96 all docs	96 docs citations	96 times ranked	9062 citing authors

#	Article	IF	Citations
1	Colon epithelial cell TGFÎ² signaling modulates the expression of tight junction proteins and barrier function in mice. American Journal of Physiology - Renal Physiology, 2021, 320, G936-G957.	3.4	23
2	Inhibition of AURKA Reduces Proliferation and Survival of Gastrointestinal Cancer Cells With Activated KRAS by Preventing Activation of RPS6KB1. Gastroenterology, 2019, 156, 662-675.e7.	1.3	56
3	Adenomaâ€like adenocarcinoma: a subtype of colorectal carcinoma with good prognosis, deceptive appearance onÂbiopsy and frequent <scp>KRAS</scp> mutation. Histopathology, 2016, 68, 183-190.	2.9	23
4	Claudin-7 expression induces mesenchymal to epithelial transformation (MET) to inhibit colon tumorigenesis. Oncogene, 2015, 34, 4570-4580.	5.9	75
5	Small molecule/ML327 mediated transcriptional de-repression of E-cadherin and inhibition of epithelial-to-mesenchymal transition. Oncotarget, 2015, 6, 22934-22948.	1.8	11
6	Claudin-1 regulates intestinal epithelial homeostasis through the modulation of Notch-signalling. Gut, 2014, 63, 622-634.	12.1	163
7	Nuclear Factor of Activated T-cell Activity Is Associated with Metastatic Capacity in Colon Cancer. Cancer Research, 2014, 74, 6947-6957.	0.9	96
8	Fibrogenesis in pancreatic cancer is a dynamic process regulated by macrophageâ€“stellate cell interaction. Laboratory Investigation, 2014, 94, 409-421.	3.7	58
9	Elevated ALCAM Shedding in Colorectal Cancer Correlates with Poor Patient Outcome. Cancer Research, 2013, 73, 2955-2964.	0.9	34
10	Four Jointed Box 1 Promotes Angiogenesis and Is Associated with Poor Patient Survival in Colorectal Carcinoma. PLoS ONE, 2013, 8, e69660.	2.5	27
11	Deciphering Genomic Alterations in Colorectal Cancer through Transcriptional Subtype-Based Network Analysis. PLoS ONE, 2013, 8, e79282.	2.5	15
12	Prognostic gene expression signature associated with two molecularly distinct subtypes of colorectal cancer. Gut, 2012, 61, 1291-1298.	12.1	74
13	XIAP Monoubiquitylates Groucho/TLE to Promote Canonical Wnt Signaling. Molecular Cell, 2012, 45, 619-628.	9.7	72
14	A Network-Based Gene Expression Signature Informs Prognosis and Treatment for Colorectal Cancer Patients. PLoS ONE, 2012, 7, e41292.	2.5	35
15	Kaiso Directs the Transcriptional Corepressor MTG16 to the Kaiso Binding Site in Target Promoters. PLoS ONE, 2012, 7, e51205.	2.5	22
16	Identification and Optimization of Small Molecules That Restore E-Cadherin Expression and Reduce Invasion in Colorectal Carcinoma Cells. ACS Chemical Biology, 2011, 6, 452-465.	3.4	35
17	Claudin-2 expression increases tumorigenicity of colon cancer cells: role of epidermal growth factor receptor activation. Oncogene, 2011, 30, 3234-3247.	5.9	133
18	BVES regulates EMT in human corneal and colon cancer cells and is silenced via promoter methylation in human colorectal carcinoma. Journal of Clinical Investigation, 2011, 121, 4056-4069.	8.2	60

#	Article	IF	Citations
19	HDAC inhibitors regulate claudin-1 expression in colon cancer cells through modulation of mRNA stability. Oncogene, 2010, 29, 305-312.	5.9	83
20	Increased cell migration and plasticity in Nrf2-deficient cancer cell lines. Oncogene, 2010, 29, 3703-3714.	5.9	88
21	Loss of Rab25 promotes the development of intestinal neoplasia in mice and is associated with human colorectal adenocarcinomas. Journal of Clinical Investigation, 2010, 120, 840-849.	8.2	134
22	Identification of Early Intestinal Neoplasia Protein Biomarkers Using Laser Capture Microdissection and MALDI MS. Molecular and Cellular Proteomics, 2009, 8, 936-945.	3.8	24
23	Oncogenic Ras and Transforming Growth Factor-Î² Synergistically Regulate AU-Rich Elementâ€“Containing mRNAs during Epithelial to Mesenchymal Transition. Molecular Cancer Research, 2008, 6, 1124-1136.	3.4	38
24	Smad4 Regulates Claudin-1 Expression in a Transforming Growth Factor-Î²â€“Independent Manner in Colon Cancer Cells. Cancer Research, 2007, 67, 1571-1579.	0.9	71
25	Urine PGE-M: A Metabolite of Prostaglandin E2 as a Potential Biomarker of Advanced Colorectal Neoplasia. Clinical Gastroenterology and Hepatology, 2006, 4, 1358-1365.	4.4	74
26	Roles for transforming growth factor-Î± and transforming growth factor-ÃŸ in colorectal cancer. Current Colorectal Cancer Reports, 2006, 2, 72-77.	0.5	0
27	Role of Smad proteins in the regulation of NF-Î³B by TGF-Î² in colon cancer cells. Cellular Signalling, 2006, 18, 1041-1050.	3.6	43
28	Smad4-dependent Regulation of Urokinase Plasminogen Activator Secretion and RNA Stability Associated with Invasiveness by Autocrine and Paracrine Transforming Growth Factor-Î². Journal of Biological Chemistry, 2006, 281, 33971-33981.	3.4	42
29	Oncogenic Function of a Novel WD-Domain Protein, STRAP, in Human Carcinogenesis. Cancer Research, 2006, 66, 6156-6166.	0.9	77
30	Neoadjuvant Concurrent Paclitaxel and Radiation in Stage II/III Breast Cancer. Clinical Cancer Research, 2006, 12, 1570-1576.	7.0	67
31	Resident Work Hour Limits and Patient Safety. Annals of Surgery, 2005, 241, 847-860.	4.2	111
32	A phase I study of concurrent 9-nitro-20(s)-camptothecin (9NC/Orathecin) and radiation therapy in the treatment of locally advanced adenocarcinoma of the pancreas. Radiotherapy and Oncology, 2005, 76, 54-58.	0.6	9
33	Smad7 induces tumorigenicity by blocking TGF-Î²-induced growth inhibition and apoptosis. Experimental Cell Research, 2005, 307, 231-246.	2.6	117
34	A Specific Inhibitor of TGF-Î² Receptor Kinase, SB-431542, as a Potent Antitumor Agent for Human Cancers. Neoplasia, 2005, 7, 509-521.	5.3	239
35	Claudin-1 regulates cellular transformation and metastatic behavior in colon cancer. Journal of Clinical Investigation, 2005, 115, 1765-1776.	8.2	456
36	Enhanced Tumor Formation in Cyclin D1 Ã— Transforming Growth Factor Î²1 Double Transgenic Mice with Characterization by Magnetic Resonance Imaging. Cancer Research, 2004, 64, 1315-1322.	0.9	27

#	Article	IF	Citations
37	Smad3 has a critical role in TGF-Î²-mediated growth inhibition and apoptosis in colonic epithelial cells. Journal of Surgical Research, 2004, 117, 296-305.	1.6	36
38	Over-expression of cyclin D1 regulates Cdk4 protein synthesis. Cell Proliferation, 2003, 36, 347-360.	5.3	10
39	A conditionally replicating adenovirus targeted to tumor cells through activated RAS/P-MAPK-selective mRNA stabilization. Nature Biotechnology, 2003, 21, 771-777.	17.5	42
40	Lymphatic Mapping and Sentinel Lymphadenectomy After Preoperative Therapy for Stage II and III Breast Cancer. Annals of Surgical Oncology, 2003, 10, 616-621.	1.5	92
41	Dysregulation of E-cadherin by oncogenic ras in intestinal epithelial cells is blocked by inhibiting MAP kinase. American Journal of Surgery, 2003, 186, 426-430.	1.8	18
42	Regulation of Cyclooxygenase-2 Expression by the Translational Silencer TIA-1. Journal of Experimental Medicine, 2003, 198, 475-481.	8.5	190
43	Vascular Endothelial Growth Factor-Mediated Angiogenesis Inhibition and Postoperative Wound Healing in Rats. Journal of Surgical Research, 2002, 105, 43-47.	1.6	81
44	New Strategies for Colorectal Cancer Prevention and Treatment. World Journal of Surgery, 2002, 26, 762-766.	1.6	26
45	Cyclin D3 Is Essential for Intestinal Epithelial Cell Proliferation. World Journal of Surgery, 2002, 26, 812-818.	1.6	8
46	Induction of Cyclooxygenase-2 and Invasiveness by Transforming Growth Factor-Î²1 in Immortalized Mouse Colonocytes Expressing Oncogenic Ras,. Journal of Gastrointestinal Surgery, 2002, 6, 304-309.	1.7	15
47	Transforming Growth Factor-Î²1 Promotes Invasiveness after Cellular Transformation with Activated Ras in Intestinal Epithelial Cells. Experimental Cell Research, 2001, 266, 239-249.	2.6	74
48	TGF-? and colorectal carcinogenesis. Microscopy Research and Technique, 2001, 52, 450-457.	2.2	42
49	A phase I study of vitamin E, 5-fluorouracil and leucovorin for advanced malignancies. Investigational New Drugs, 2001, 19, 21-27.	2.6	9
50	Oncogenic Ras Represses Transforming Growth Factor-Î²/Smad Signaling by Degrading Tumor Suppressor Smad4. Journal of Biological Chemistry, 2001, 276, 29531-29537.	3.4	106
51	Hepatocellular carcinoma results from chronic cyclin D1 overexpression in transgenic mice. Cancer Research, 2001, 61, 5389-95.	0.9	144
52	Transforming Growth Factor-Î²1 Enhances Ha-ras-induced Expression of Cyclooxygenase-2 in Intestinal Epithelial Cells via Stabilization of mRNA. Journal of Biological Chemistry, 2000, 275, 6628-6635.	3.4	175
53	Oncogenic Ras-mediated Cell Growth Arrest and Apoptosis are Associated with Increased Ubiquitin-dependent Cyclin D1 Degradation. Journal of Biological Chemistry, 2000, 275, 22916-22924.	3.4	70
54	Inhibition of pRb phosphorylation and cell cycle progression by an antennapedia-p16INK4A fusion peptide in pancreatic cancer cells. Cancer Letters, 2000, 159, 151-158.	7.2	37

#	Article	IF	Citations
55	Presidential address: Evolution. Surgery, 2000, 128, 123-132.	1.9	3
56	Posttranscriptional Regulation of Cyclooxygenase-2 in Rat Intestinal Epithelial Cells. Neoplasia, 2000, 2, 523-530.	5.3	63
57	Coordinate regulation of cyclooxygenase-2 and TGF-1 in replication error-positive colon cancer and azoxymethane-induced rat colonic tumors. Carcinogenesis, 1999, 20, 185-191.	2.8	72
58	Transformation of intestinal epithelial cells by chronic TGF-Î²1 treatment results in downregulation of the type II TGF-Î² receptor and induction of cyclooxygenase-2. Oncogene, 1999, 18, 855-867.	5.9	58
59	Synergistic Induction of Cyclooxygenase-2 by Transforming Growth Factor-Î²1 and Epidermal Growth Factor Inhibits Apoptosis in Epithelial Cells. Neoplasia, 1999, 1, 508-517.	5.3	72
60	18Fluorodeoxyglucose-Positron Emission Tomography in the Management of Patients With Suspected Pancreatic Cancer. Annals of Surgery, 1999, 229, 729.	4.2	170
61	TGF-Î²1 effects on proliferation of rat intestinal epithelial cells are due to inhibition of cyclin D1 expression. Oncogene, 1998, 16, 3445-3454.	5.9	77
62	Nuclear translocation of beta-catenin in hereditary and carcinogen- induced intestinal adenomas. Carcinogenesis, 1998, 19, 543-549.	2.8	71
63	Induction of Cyclooxygenase-2 by Activated Ha-rasOncogene in Rat-1 Fibroblasts and the Role of Mitogen-activated Protein Kinase Pathway. Journal of Biological Chemistry, 1998, 273, 22120-22127.	3.4	161
64	Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Research, 1998, 58, 362-6.	0.9	843
65	A selective cyclooxygenase 2 inhibitor suppresses the growth of H-ras-transformed rat intestinal epithelial cells. Gastroenterology, 1997, 113, 1883-1891.	1.3	164
66	Antioxidants enhance the cytotoxicity of chemotherapeutic agents in colorectal cancer: A p53-independent induction of p21WAF1/CIP1 via C/EBPÎ². Nature Medicine, 1997, 3, 1233-1241.	30.7	309
67	Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2.. Journal of Clinical Investigation, 1997, 99, 2254-2259.	8.2	612
68	Concurrent overexpression of cyclin D1 and cyclin-dependent kinase 4 (Cdk4) in intestinal adenomas from multiple intestinal neoplasia (Min) mice and human familial adenomatous polyposis patients. Cancer Research, 1997, 57, 169-75.	0.9	89
69	Decreased transforming growth factor beta type II receptor expression in intestinal adenomas from Min/+ mice is associated with increased cyclin D1 and cyclin-dependent kinase 4 expression. Cancer Research, 1997, 57, 1638-43.	0.9	25
70	Short-term caloric restriction augments age-related decreases in gastrin content and release. Mechanisms of Ageing and Development, 1996, 87, 25-33.	4.6	3
71	Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterology, 1996, 111, 1134-1140.	1.3	276
72	Intestinal Cell Cycle Regulation. Annals of Surgery, 1996, 223, 620-628.	4.2	21

#	Article	IF	Citations
73	Differential regulation by TGF-beta 1 and insulin of insulin-like growth factor binding protein-2 in IEC-6 cells. American Journal of Physiology - Endocrinology and Metabolism, 1995, 268, E1199-E1204.	3.5	6
74	Transforming growth factor-beta 1 inhibits cyclin D1 expression in intestinal epithelial cells. Oncogene, 1995, 10, 177-84.	5.9	113
75	Transforming growth factor-Î² inhibits rat intestinal cell growth by regulating cell cycle specific gene expression. American Journal of Surgery, 1994, 167, 14-20.	1.8	40
76	Activation of hepatic proliferation-associated transcription factors by lipopolysaccharide. Surgery, 1994, 116, 367-76; discussion 376-7.	1.9	1
77	Phenotypic alterations in fibroblasts and fibrosarcoma cells that overexpress latent transforming growth factor-beta 1.. Endocrinology, 1992, 130, 2476-2486.	2.8	13
78	Posttranscriptional regulation of albumin and alpha-fetoprotein messenger RNA by transforming growth factor-beta 1 requires de novo RNA and protein synthesis.. Molecular Endocrinology, 1992, 6, 1789-1796.	3.7	10
79	The role of endogenous prostaglandins in hormone-stimulated pancreatic exocrine secretion. Gastroenterology, 1992, 102, 272-279.	1.3	4
80	Transforming Growth Factor (TGF)-Î² Stimulates Hepatic and Proto-oncogenes and Decreases Albumin mRNA. Annals of Surgery, 1992, 216, 300-308.	4.2	11
81	Unexpected growth-stimulatory effect of somatostatin analogue on cultured human pancreatic carcinoid cells. Biochemical and Biophysical Research Communications, 1992, 185, 577-581.	2.1	18
82	Receptorâ€mediated autocrine growthâ€stimulatory effect of 5â€hydroxytryptamine on cultured human pancreatic carcinoid cells. Journal of Cellular Physiology, 1992, 150, 1-7.	4.1	72
83	Posttranscriptional regulation of albumin and alpha-fetoprotein messenger RNA by transforming growth factor-beta 1 requires de novo RNA and protein synthesis. Molecular Endocrinology, 1992, 6, 1789-1796.	3.7	8
84	Systemic alterations in ornithine decarboxylase activity caused by colon cancer in mice. Cancer Letters, 1991, 58, 155-158.	7.2	2
85	Differential Effects of Sodium Butyrate and Hexamethylene Bisacetamide on Growth and Secretion of Cultured Human Endocrine Tumor Cells. Archives of Surgery, 1991, 126, 467.	2.2	5
86	Human carcinoid cell production of paracrine growth factors that can stimulate fibroblast and endothelial cell growth. Cancer Research, 1991, 51, 5253-60.	0.9	54
87	Expression of and Response to Growth Regulatory Peptides by Two Human Pancreatic Carcinoma Cell Lines. Pancreas, 1990, 5, 369-380.	1.1	66
88	A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 1486-1490.	7.1	372
89	Proglumide inhibits cholecystokinin and meal-stimulated pancreatic secretion and release of pancreatic polypeptide. Surgery, 1990, 108, 553-8.	1.9	0
90	Regulation of intestinal epithelial cell growth by transforming growth factor type beta.. Proceedings of the National Academy of Sciences of the United States of America, 1989, 86, 1578-1582.	7.1	308

#	Article	IF	Citations
91	Localization of transforming growth factor alpha and its receptor in gastric mucosal cells. Implications for a regulatory role in acid secretion and mucosal renewal.. Journal of Clinical Investigation, 1989, 84, 1017-1023.	8.2	231
92	Operative strategies in the management of mediastinal pancreatic pseudocyst. Surgery, 1989, 106, 567-70.	1.9	6
93	Growth factors and intestinal neoplasms. American Journal of Surgery, 1988, 155, 526-536.	1.8	51
94	A High Pressure Liquid Chromatography-Radioimmunoassay Method for Measurement of Cholecystokinin-8 and Cholecystokinin-33/39 in Plasma. Journal of Liquid Chromatography and Related Technologies, 1987, 10, 1431-1438.	1.0	5
95	Role of cholecystokinin in canine pancreatic exocrine response to bombesin stimulation. American Journal of Surgery, 1987, 153, 96-101.	1.8	20
96	Proglumide, A Gastrin Receptor Antagonist, Inhibits Growth of Colon Cancer and Enhances Survival in Mice. Annals of Surgery, 1985, 202, 303-309.	4.2	104